NYXH Nyxoah

Publication Relating to a Transparency Notification

Publication Relating to a Transparency Notification

                

REGULATED INFORMATION

Publication Relating to a Transparency Notification

Mont-Saint-Guibert (Belgium), July 27, 2023, 10.30pm CET / 4.30pm ET In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a rectification of an earlier transparency notification.

On July 25, 2023, Nyxoah received the rectification of the April 16, 2023 transparency notification that it had received from ResMed Inc. in relation to the upward crossing of the 5% threshold by ResMed Inc. on March 30, 2023. The correction relates to the number of shares and the percentage of voting rights held by ResMed Inc. on March 30, 2023: ResMed Inc. held 1,619,756 shares, representing 5.73% of the total number of voting rights (and not 1,499,756 shares or 5.30% of the voting rights as stated in the April 2023 notification).

The notification dated July 17, 2023 contains the following information:

  • Reason for the notification: acquisition or disposal of voting securities or voting rights
  • Notification by: a person that notifies alone
  • Persons subject to the notification requirement: ResMed Inc., 9001 Spectrum Center Boulevard, San Diego, CA 92123, USA
  • Date on which the threshold was crossed: March 30, 2023
  • Threshold that is crossed: 5%
  • Denominator: 28,286,985
  • Notified details:



A) Voting rightsPrevious notificationAfter the transaction
 # of voting rights# of voting rights% of voting rights
Holders of voting rights Linked to securitiesNot linked to the

securities
Linked to securitiesNot linked to the

securities
ResMed Inc.794,2351,619,756 5.73% 
 TOTAL1,619,756 05.73%0.00%
  • Chain of controlled undertakings through which the holding is effectively held: No indirect holding of voting securities. ResMed Inc. is not a controlled entity.



*

* *

Contact:

Nyxoah

David DeMartino, Chief Strategy Officer



Attachment



EN
27/07/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nyxoah

 PRESS RELEASE

Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity...

Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth Mont-Saint-Guibert, Belgium – January 21, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced an important investment in Belgium to further scale its manufacturing capacity to suppo...

 PRESS RELEASE

Nyxoah Investit Dans l'Expansion De Sa Capacité De Production En Belgi...

Nyxoah Investit Dans l'Expansion De Sa Capacité De Production En Belgique Afin De Soutenir Sa Croissance Mondiale Nyxoah Investit Dans l'Expansion De Sa Capacité De Production En Belgique Afin De Soutenir Sa Croissance Mondiale Mont-Saint-Guibert, Belgique – 21 janvier 2026, 22h05 CET / 16h05 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » ou la « Société ») une société de technologie médicale spécialisée dans le développement et la commercialisation de solutions innovantes pour le traitement de l'Apnée Obstructive du Sommeil (« AOS ») par neuromodulation, a annoncé aujourd'h...

Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
 PRESS RELEASE

Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Y...

Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026 INSIDE INFORMATIONREGULATED INFORMATION Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026 Strong Start in First Full Quarter of U.S. Commercialization Mont-Saint-Guibert, Belgium – January 12, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment a...

 PRESS RELEASE

Nyxoah Annonce ses Résultats Préliminaires pour le Quatrième Trimestre...

Nyxoah Annonce ses Résultats Préliminaires pour le Quatrième Trimestre et l'Ensemble de l'Exercice 2025 et Communique des Prévisions de Chiffre d'Affaires pour le Premier Trimestre 2026 INFORMATIONS PRIVILÉGIÉESINFORMATIONS RÉGLEMENTÉES Nyxoah Annonce ses Résultats Préliminaires pour le Quatrième Trimestre et l'Ensemble de l'Exercice 2025 et Communique des Prévisions de Chiffre d'Affaires pour le Premier Trimestre 2026 Un Démarrage Solide pour le Premier Trimestre Complet de Commercialisation aux États-Unis Mont-Saint-Guibert, Belgique – 12 janvier 2026, 22h05 CET / 16h05 ET – Nyxoah SA ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch